Repurposing Novobiocin as an Antiviral Against SFTSV: Insights and Evidence

Study Background and Research Question

Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus that poses a significant public health threat in East Asia due to its high mortality rates and lack of approved antiviral therapies. SFTSV infection can lead to severe multisystem disease, with limited treatment options beyond supportive care. Given the urgency of developing effective interventions, the referenced study (Journal of Medical Virology, 2025) set out to explore drug repurposing as a rapid pathway to identify potential antiviral agents against SFTSV.

Key Innovation from the Reference Study

The core innovation lies in the systematic in vitro evaluation of 19 FDA-approved compounds—including antibiotics, antivirals, and other small molecules—for their ability to inhibit SFTSV replication in human cell culture. Notably, the study identified Novobiocin, an aminocoumarin antibiotic traditionally used for its antibacterial properties, as a candidate with significant antiviral activity against SFTSV. This unexpected cross-domain efficacy suggests that some established antimicrobials may have overlooked potential as antiviral compounds.

Methods and Experimental Design Insights

The investigators employed a robust cell-based screening pipeline to assess antiviral efficacy and cytotoxicity:

• Human cell lines were infected with a clinical isolate of SFTSV and treated with each compound at multiple concentrations.
• Antiviral activity was quantified by measuring the reduction in SFTSV nucleoprotein expression using immunofluorescence analysis.
• Cytotoxicity was evaluated in parallel to ensure selectivity of action.
• Effective concentration (EC₅₀) values were calculated to benchmark potency.

Three compounds—Simeprevir, Novobiocin, and Levofloxacin hydrochloride—emerged as top candidates. Novobiocin displayed an EC₅₀ of 25.12 μM, with minimal cytotoxicity at active concentrations, while Simeprevir and Levofloxacin hydrochloride showed EC₅₀ values of 0.009774 μM and 46.30 μM, respectively.

Core Findings and Why They Matter

The study demonstrated that Novobiocin significantly inhibited SFTSV replication in vitro in a dose-dependent manner, as evidenced by reduced viral nucleoprotein expression (reference). Importantly, the compound’s antiviral effect was not confounded by overt cytotoxicity, supporting its selectivity as an antiviral compound. These results underscore several key points:

• Antiviral potential of aminocoumarin antibiotics: Novobiocin’s efficacy suggests that targeting host or viral replication machinery can extend beyond classic antibacterial indications, potentially informing the design of novel antiviral strategies.
• Drug repurposing accelerates translational research: By leveraging compounds with known pharmacological and safety profiles, researchers can rapidly identify and prioritize candidates for further preclinical evaluation against emerging viral threats.
• Mechanistic overlap: While Novobiocin is well-characterized as a bacterial DNA gyrase inhibitor and Hsp90 inhibitor, its observed activity against SFTSV raises questions about possible interference with viral replication pathways or host chaperone machinery relevant to viral life cycles.

Comparison with Existing Internal Articles

The findings from the reference study align with a growing body of literature exploring the versatility of Novobiocin as both an antibacterial and antiparasitic agent. For instance, the article "Quinolone–Coumarin Hybrids and Novobiocin Against Toxoplasma gondii" documents the efficacy of Novobiocin and related hybrids against T. gondii, expanding its profile as an antiparasitic agent. Similarly, "Novobiocin’s Hsp90 Inhibition: Anti-piroplasmic Efficacy in Equine Parasites" highlights the role of Hsp90 inhibition in combating protozoan parasites such as Theileria equi and Babesia caballi, with low cytotoxicity profiles. These cross-domain findings, together with the current antiviral evidence, suggest that Novobiocin’s multi-targeted mechanisms—namely, DNA gyrase inhibition and interference with protein folding via Hsp90—may underlie its broad-spectrum activity across bacteria, parasites, and now, select viruses. The workflow-focused article "Novobiocin: Applied Workflows in Antibacterial & Antiparasitic Research" provides further guidance on protocol optimization, which may inform parallel assay development in antiviral research.

Protocol Parameters

• In vitro antiviral assays: The reference study used Novobiocin at concentrations up to 50 μM, with dose-dependent antiviral effects observed and minimal cytotoxicity.
• Suggested working concentrations: For antiparasitic and antiviral studies, concentrations typically range from 1 to 200 μM, while 50 μg/ml is recommended for bacterial protoplast inhibition (product information).
• Compound preparation: Novobiocin is soluble at ≥52.4 mg/mL in DMSO and ≥53.4 mg/mL in ethanol, but insoluble in water; use freshly prepared solutions and store at -20°C, desiccated.
• In vivo reference: Intraperitoneal doses in mice can be tolerated up to 100 mg/kg, with a NOAEL of 50 mg/kg, while oral dosing achieves relevant blood levels in dogs and humans.

Why this cross-domain matters, maturity, and limitations

The extension of Novobiocin’s utility from antibacterial and antiparasitic contexts into antiviral research reflects a broader trend toward multi-targeted, mechanistically flexible agents. However, while in vitro results are promising, the translation to clinically effective antivirals requires substantial validation in animal models and, eventually, human trials. The current evidence is limited to cell-based assays, and the precise antiviral mechanism in the context of SFTSV remains to be elucidated. Potential pharmacokinetic or toxicity issues at therapeutic doses must also be considered before Novobiocin can be repositioned as an antiviral agent.

Limitations and Transferability

Although Novobiocin shows clear in vitro activity against SFTSV with favorable selectivity (reference), several caveats apply:

• Results are limited to a single virus and cell culture model; broader antiviral spectrum and in vivo relevance remain untested in this context.
• Potential off-target effects or host toxicity at higher exposures need to be systematically ruled out in animal studies.
• The mechanistic basis for antiviral activity is not fully resolved—whether it reflects host chaperone inhibition, viral enzyme interference, or other pathways.
• Clinical translation will depend on further optimization of dosing, delivery, and safety, especially given historical challenges with aminocoumarin antibiotics in systemic use.

Research Support Resources

For researchers seeking to replicate or extend these findings, Novobiocin (SKU BA1116) is available with detailed physicochemical and protocol guidance. APExBIO provides relevant working concentrations and storage recommendations to facilitate workflow design in both antiparasitic and antiviral research. When building on the cross-domain findings highlighted above, consider aligning assay conditions and controls with those validated in the referenced antiviral and internal antiparasitic studies to optimize reproducibility.